Profile of Serum Interferon Gamma Induced Protein 10 in Borderline Leprosy Patients with and without Type 1 Leprosy Reaction
Downloads
Eichelmann K, Gonzalez Gonzales SE, Salas-Alanis JC, Ocampo-Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis and treatment. Actas Dermosifiliogr 2013; 104(7): 554-63.
Global leprosy situation, 2013. Wkly Epidemiol Rec 2014; 89(36): 389-400.
Walker SL, Lockwood DNJ. The clinical and immunological features of lerosy. Brit Med Bulletin 2006; 77-78: 103-21.
Pratamasari MA, Listyawan MY. Studi retrospektif: reaksi kusta tipe 1. Berkala Ilmu Kesehatan Kulit Kelamin 2015; 27(2): 137-43.
Kahawita Indira P, Walker Stephen L, Lockwood Diana N.J. Leprosy type 1 reactions and erythema nodosum leprosum. An Bras Dermatol 2008; 83(1): 75-82.
Nath I, Saini C, Valluri VL. Immunology of human leprosy and diagnostic challenges. Clin Dermatol 2015; 33:90-8.
Geyer AI, Kraus T, Roberts M, Wisnivesky J, Eber CD, Hiensch R, et al. Plasma level of interferon γ induced protein 10 is a marker of sarcoidosis disease activity. Cytokine 2013; 64(1):152–7.
Ferrari SM, Ruffilli I, Colaci M, Antonelli A, Ferri C, Fallahi P. CXCL10 in psoriasis. Adv Med Sci 2015 Sep 30; 60(2):349-54.
Scollard DM, Chadvula MV, Martinez A, Fowlkes N, Nath I, Stryjewska BM et al. Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions. Clin Vaccine Immunol 2011; p. 947-53.
Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22: 121–30.
Stefani MM, Guerra JG, Sousa ALM, Costa MB, Oliviera MLW, Martelli CT et al. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Inf Dis 2009; 9: 75-9.
Suchonwanit P, Triamchaisri S, Wittayakornrerk S, Rattanakaemakorn P. Leprosy reaction in Thai population: a 20-year retrospective study. Dermatol Res Pract 2015; 3:1-5.
Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol 2013; 79:739-49.
Prakoeswa CRS, Siswati AS. Reaksi Tipe 1: Diagnosis dan Penatalaksanaannya. Dalam: Prakoeswa CRS, Agusni I, Listiawan MY, editor. Kapita Selekta Penatalaksanaan Morbus Hansen Terkini. Surabaya: Dept/SMF Ilmu Kesehatan Kulit dan Kelamin 2013. h. 41-9.
Gameiro CM, Romí£o F, Castelo-Branco C: Menopause and aging: changes in the immune system–a review. Maturitas 2010; 67:316–20.
World Health Organization. Transmission of leprosy. [Internet]. [Cited 2016 Oktober 22]. Available from: http://www.who.int/lep/transmission/en/
Kar HK, Sharma P. Leprosy Reactions. In: Kar HK, Kumar B, editors. Indian Association of Leprologist Textbook of Leprosy. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2010. p. 269-89.
Wahyuni ET, Amiruddin MD, Vitayani S. Reversal reaction in tuberculoid leprosy. IJDV 2012; 1(2):69-74.
Nery JAC, Machado AM, Bernardes-Filho F, Oliveira SSC, Quintanilha J, Sales AM. Understanding the type 1 reactional state for
early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol 2013;88(5):787-92.
White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev 2015; 28:80 –94.
Listiawan MY, Agusni I, Martodiharjo S. Lepra. Dalam: Departemen/SMF Ilmu Kesehatan Kulit dan Kelamin. Pedoman Diagnosis dan Terapi. Edisi ke-3. Surabaya: Airlangga University Press 2012. h. 41-5.
Kumaran SM, Bhat IP, Madhukara J, Rout P, Elizabeth J. Comparison of bacillary index on slit skin smear with bacillary index of granuloma in leprosy and its relevance to present therapeutic regimens. Indian J Dermatol 2015; 60(1): 51–4.
Antunes DE, Araujo S, Ferreira GP, Rodrigues da Cunha ACS, Viera da Costa A, Goncalves MA et al. Indentification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and afrer multidrug therapy. Mern Ins Oswaldo Cruz 2013; 108(7): 901-8.
Chaitanya,VS, Lavaniaa M, Nigama A, Turankara RP, Singha I, Horob I et al. Cortisol and proinflammatory cytokine profiles in type 1 (reversal) reactions of leprosy. Immunol Lett 2013; 156:159-67.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.